ATEC Stock Charts

Quarterly

Annual

Unit: USD	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30

operating activities:
net income	-28,578,000	-41,144,000	-51,907,000	-33,332,000	-39,616,000	-40,680,000	-48,495,000	-49,078,000	-42,654,000	-51,377,000	-43,529,000	-34,986,000	-36,999,000	-37,320,000	-42,844,000	-40,187,000	-43,031,000	-38,205,000	-22,903,000	-26,798,000	-15,669,000	-15,805,000	-20,722,000	-17,031,000	-14,567,000	-12,436,000	-12,968,000	-10,628,000	-9,355,000	-7,076,000	-1,916,000	9,055,000	-3,137,000	-2,697,000	-5,515,000	-4,354,000	-13,721,000	-5,233,000	-6,617,000	-9,903,000	-160,265,000	-3,947,000	-4,561,000	-273,000	-3,041,000	-2,895,000	-6,673,000	-60,407,000	-14,510,000	-4,661,000	-2,649,000	-5,355,000	-2,469,000	-6,374,000	-1,261,000	-15,966,000	-1,304,000	-3,044,000	-1,867,000	-2,876,000	-3,790,000	-2,979,000	-4,710,000	-1,320,000	-1,283,000	-6,303,000	-4,383,000	-5,058,000	-4,860,000	-3,591,000	-15,779,000	-11,247,000	-5,578,000	-703,000	-2,674,000	-11,324,000	-5,438,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	19,156,000	19,328,000	19,907,000	20,008,000	20,648,000	19,877,000	17,885,000	16,019,000	14,745,000	13,683,000	11,692,000	11,349,000	10,812,000	9,692,000	9,315,000	8,770,000	7,592,000	6,544,000	3,850,000	3,145,000	2,748,000	2,602,000	2,454,000	2,224,000	1,924,000	1,645,000	1,785,000	1,723,000	1,591,000	1,589,000	1,886,000	1,945,000	1,798,000	1,870,000	1,868,000	1,961,000	3,022,000	3,497,000	3,884,000	4,932,000	4,512,000	5,425,000	4,162,000	4,379,000	4,451,000	4,704,000	4,851,000	6,313,000	7,375,000	6,330,000	6,259,000	6,369,000	5,800,000	5,820,000	5,803,000	4,937,000	4,957,000	4,979,000	5,003,000	4,795,000	4,614,000	4,275,000	3,562,000	3,312,000	3,146,000	2,897,000	2,601,000	2,816,000	2,242,000	1,638,000	2,035,000	2,793,000	2,742,000	2,527,000	2,410,000	2,609,000	1,979,000
stock-based compensation	16,379,000	15,624,000	22,318,000	21,533,000	17,462,000	16,960,000	17,322,000	20,515,000	20,073,000	24,194,000	16,462,000	10,092,000	11,077,000	9,203,000	10,184,000	9,726,000	10,754,000	11,496,000	4,474,000	4,972,000	4,544,000	4,575,000	3,568,000	3,390,000	3,603,000	2,351,000	1,612,000	1,862,000	1,675,000	1,148,000	619,000	2,233,000	709,000	444,000	516,000	116,000	1,147,000	305,000	58,000	203,000	-78,000	1,265,000	1,253,000	913,000	1,502,000	1,195,000	944,000	1,246,000	853,000	795,000	1,184,000	1,480,000	1,000,000	663,000	547,000	497,000	480,000	734,000	714,000	851,000	573,000	772,000	981,000	1,008,000	1,098,000	831,000	634,000	672,000	823,000	671,000	769,000	600,000	236,000	-773,000	251,000	4,139,000	1,164,000
amortization of debt discount and debt issuance costs	6,703,000	6,505,000	2,418,000	1,183,000	1,160,000	1,061,000	1,058,000	1,048,000	876,000	1,013,000	697,000	568,000	497,000	484,000	489,000			652,000	640,000	841,000	757,000	1,138,000	1,238,000	1,377,000	1,299,000	530,000	503,000	516,000	481,000	501,000	589,000
amortization of right-of-use assets	1,222,000	1,194,000	1,271,000	1,403,000	1,274,000	1,194,000	1,031,000	945,000	909,000	858,000	831,000	833,000	799,000	565,000	563,000	688,000	780,000	928,000	1,022,000
write-down for excess and obsolete inventories	3,379,000	4,373,000	3,571,000	4,451,000	4,113,000	3,878,000	2,979,000	4,420,000	2,454,000	4,636,000	2,098,000	2,769,000	2,923,000	2,394,000	1,706,000
loss on disposal of assets	595,000	137,000	1,563,000	-190,000	1,111,000	1,319,000	832,000	1,499,000	807,000	686,000	716,000	855,000	545,000	720,000	474,000
loss on debt extinguishment	0	0	17,576,000
gain on derivative liability	0	16,780,000	-17,400,000
other	1,455,000	-104,000	4,252,000	201,000	5,000	3,333,000	1,655,000	-1,262,000	857,000	270,000	590,000	614,000	699,000	117,000	-243,000	1,860,000	-1,130,000																																		285,000				242,000													0	0	0	22,000
changes in operating assets and liabilities:
accounts receivable	-2,256,000	-5,967,000	-10,282,000	-5,110,000	5,814,000	1,765,000	-17,058,000	-7,857,000	-5,036,000	2,576,000	-2,478,000	-8,699,000	-7,878,000	-3,929,000	1,674,000	-8,724,000	-156,000	630,000	-1,891,000	715,000	-4,542,000	-4,439,000	782,000	-772,000	-1,856,000	62,000	1,268,000	-2,923,000	-819,000	500,000	2,846,000	-1,201,000	-104,000	1,102,000	4,356,000	-2,658,000	7,725,000	3,530,000	-597,000	-2,278,000	2,609,000	-397,000	1,263,000	-1,401,000	3,047,000	-5,234,000	2,560,000	-236,000	-394,000	-636,000	-674,000	-2,986,000	1,733,000	950,000	685,000	-3,085,000	1,245,000	-399,000	-2,765,000	2,966,000	-4,870,000	505,000	-780,000	-3,159,000	2,379,000	113,000	-5,381,000	-1,040,000	-2,094,000	-1,420,000	-719,000	192,000	-907,000	541,000	-1,295,000	-186,000
inventories	-594,000	-2,158,000	1,243,000	2,384,000	-14,187,000	-23,343,000	-19,514,000	-9,475,000	-14,041,000	-13,506,000	-8,540,000	-573,000	-3,516,000	-7,461,000	-9,154,000	-3,929,000	-8,622,000	-1,724,000	-13,471,000	-5,472,000	-2,673,000	-5,306,000	-4,741,000	-3,961,000	-2,788,000	-3,565,000	-4,398,000	-2,907,000	-212,000	-172,000	-2,733,000	1,552,000	-677,000	-363,000	-254,000	-1,019,000	-4,645,000	2,970,000	-3,048,000	-3,254,000	-886,000	-630,000	-686,000	-1,214,000	-1,309,000	-586,000	-1,239,000	313,000	359,000	-1,692,000	-3,387,000	-2,178,000	-1,748,000	-1,365,000	-2,562,000	1,224,000	-3,089,000	4,037,000	-1,088,000	-1,364,000	-4,512,000	-5,358,000	-3,427,000	-1,873,000	-1,189,000	-1,023,000	-3,189,000	-2,768,000	-1,759,000	-328,000	-1,731,000	-2,972,000	-1,980,000	-1,535,000	-891,000	-993,000
prepaid expenses and other current assets	287,000	1,230,000	-807,000	-780,000	802,000	-931,000	812,000	-4,599,000	2,772,000	-6,962,000	-2,309,000	533,000	1,112,000	755,000	-1,848,000	-3,557,000	3,300,000	148,000	1,367,000	-644,000	-1,225,000	-78,000	-983,000	-77,000	-22,000	87,000	198,000	-857,000	540,000	266,000	-217,000	335,000	134,000	653,000	1,958,000	-723,000	505,000	403,000	889,000	601,000	796,000	740,000	335,000	720,000	1,503,000	2,712,000	-72,000	-1,177,000	1,080,000	153,000	394,000	487,000	48,000	-289,000	1,435,000	867,000	233,000	-423,000	664,000	-464,000	-284,000	-950,000	-432,000	1,074,000	579,000	678,000	-629,000	1,936,000	-2,762,000	-799,000	493,000	520,000	-38,000	-306,000	308,000	12,000
other assets	40,000	45,000	107,000	207,000	112,000	-644,000	-141,000	-489,000	-7,000	-85,000	40,000	731,000	-587,000	-134,000	-119,000	-58,000	-76,000			2,000				135,000	1,000	57,000	69,000	-42,000	7,000	-92,000	37,000	51,000	-20,000	26,000	291,000	0	29,000	182,000	-20,000	-21,000	-69,000	81,000	3,000	-74,000	-35,000	-39,000	-128,000	7,000	-45,000	63,000	39,000	278,000	163,000	43,000	508,000	388,000	641,000	115,000	72,000	411,000	212,000	242,000	-186,000	-44,000	14,000	196,000	229,000	13,000	-104,000	-426,000	-400,000	-318,000	14,000	-67,000	12,000	926,000	-937,000
accounts payable	-14,688,000	10,268,000	-11,918,000	-6,345,000	-6,146,000	15,382,000	6,780,000	-3,301,000	-34,000	4,504,000	5,820,000	2,359,000	-214,000	14,000	7,637,000	1,055,000	-4,095,000	1,637,000	2,160,000	2,884,000	-1,637,000	2,469,000	3,414,000	2,462,000	-781,000	1,003,000	3,319,000	-906,000	1,542,000	-428,000	-192,000	1,005,000	-51,000	1,887,000	-5,433,000	382,000	-8,324,000	173,000	2,904,000	3,486,000	-1,934,000	2,144,000	-487,000	-781,000	-2,406,000	-1,891,000	4,036,000	-1,932,000	-4,091,000	1,273,000	897,000	-1,961,000	3,511,000	-266,000	-3,083,000	1,550,000	2,280,000	-1,682,000	397,000	-3,819,000	1,905,000	-2,882,000	-407,000	-1,970,000	-142,000	-217,000	504,000	615,000	492,000	614,000	190,000	984,000	-99,000	1,528,000	-2,666,000	561,000
accrued expenses	14,637,000	-9,261,000	13,938,000		2,474,000	-8,125,000	-2,551,000		3,623,000	5,066,000	-705,000		7,790,000
lease liabilities	-1,155,000	-1,067,000	-1,349,000	-1,867,000	-1,189,000	-1,392,000	-1,047,000	-925,000	-1,107,000	-807,000	-763,000	-773,000	-851,000
contract liabilities	-1,404,000	23,000	761,000	-953,000	-291,000	-1,833,000	-184,000	-113,000	67,000	-44,000	1,883,000	-1,147,000	-946,000
other long-term liabilities	-1,138,000	-258,000	-301,000	1,309,000	1,112,000	785,000	198,000	-1,367,000	-1,589,000	-2,577,000	-829,000	-2,292,000	47,000	619,000	-716,000	601,000	3,337,000	519,000	395,000	1,975,000	-1,101,000	-1,701,000	-1,099,000	-1,101,000	-1,097,000	-1,100,000	-1,099,000	-1,100,000	-1,099,000	-1,097,000	-1,071,000
net cash from operating activities	14,040,000	15,548,000	-5,039,000	10,523,000	-5,342,000	-11,394,000	-38,438,000	-25,004,000	-17,285,000	-17,872,000	-18,324,000	-8,403,000	-14,690,000	-27,338,000	-24,712,000	-14,856,000	-23,466,000	-16,506,000	-18,604,000	-6,728,000	-9,539,000	-13,097,000	-17,048,000	-9,067,000	-9,412,000	-6,698,000	-7,944,000	-9,088,000	-7,809,000	-3,411,000	-5,300,000	-615,000	-1,639,000	-424,000	-6,051,000	-9,833,000	-10,198,000	9,862,000	210,000	4,558,000	2,168,000	5,621,000	-2,223,000	13,000	4,766,000	-8,669,000	-16,381,000	1,138,000	4,187,000	2,818,000	-336,000	-298,000	8,317,000	5,005,000	-1,431,000	2,299,000	6,553,000	2,944,000	1,612,000	-1,680,000	-1,905,000	-8,747,000	-2,501,000	-2,511,000	897,000	2,425,000	-6,359,000	-1,304,000	-4,100,000	-9,751,000	-4,324,000	-6,383,000			-4,931,000	-2,240,000
capex	-8,892,000	-9,906,000	-9,657,000	0	-15,836,000	-34,100,000	-25,517,000	3,250,000	-14,451,000	-18,757,000	-14,427,000	0	-9,931,000	-15,444,000	-8,590,000	-1,882,000	-9,050,000	-7,439,000	-7,172,000	-8,617,000	-6,299,000	-3,356,000	-1,332,000	-2,617,000	-7,644,000	-1,213,000	-283,000	-3,554,000	-164,000	-1,961,000	105,000	-2,215,000	29,000	-6,647,000	1,673,000	519,000	-3,508,000	-6,049,000	2,809,000	-3,644,000	576,000	-4,280,000	-2,576,000	-4,128,000	-3,129,000	-2,322,000	-83,000	-3,951,000	-3,294,000	-5,162,000	1,249,000	-3,636,000	-3,964,000	-4,479,000	-3,519,000	-173,000	-4,151,000	-2,219,000	-1,663,000	-2,371,000	-5,584,000	-4,928,000	-1,145,000	-2,166,000	-3,009,000	0	252,000	-2,914,000	-2,904,000	-4,669,000	-2,515,000	-1,585,000			-421,000	0
free cash flows	5,148,000	5,642,000	-14,696,000	10,523,000	-21,178,000	-45,494,000	-63,955,000	-21,754,000	-31,736,000	-36,629,000	-32,751,000	-8,403,000	-24,621,000	-42,782,000	-33,302,000	-16,738,000	-32,516,000	-23,945,000	-25,776,000	-15,345,000	-15,838,000	-16,453,000	-18,380,000	-11,684,000	-17,056,000	-7,911,000	-8,227,000	-12,642,000	-7,973,000	-5,372,000	-5,195,000	-2,830,000	-1,610,000	-7,071,000	-4,378,000	-9,314,000	-13,706,000	3,813,000	3,019,000	914,000	2,744,000	1,341,000	-4,799,000	-4,115,000	1,637,000	-10,991,000	-16,464,000	-2,813,000	893,000	-2,344,000	913,000	-3,934,000	4,353,000	526,000	-4,950,000	2,126,000	2,402,000	725,000	-51,000	-4,051,000	-7,489,000	-13,675,000	-3,646,000	-4,677,000	-2,112,000	2,425,000	-6,107,000	-4,218,000	-7,004,000	-14,420,000	-6,839,000	-7,968,000			-5,352,000	-2,240,000
investing activities:
purchase of property and equipment	-9,233,000	-10,324,000	-9,934,000		-15,836,000	-34,100,000	-31,312,000		-19,374,000	-19,139,000	-16,278,000		-9,646,000	-13,081,000	-13,257,000		-12,918,000
purchase of intangible assets	-1,658,000	-1,849,000	-1,678,000	-1,771,000	-4,042,000	-1,794,000	-2,306,000	-2,496,000	-2,009,000	-1,424,000	-538,000	-1,366,000	-5,982,000	-1,329,000	-150,000																																	0	-250,000	-250,000	-250,000	-925,000	-175,000			-245,000	0	0	-445,000	-1,800,000				0				-1,000	0			0	33,000	-18,000	-2,627,000
cash paid for equity investment
net cash from investing activities	-13,891,000	-12,173,000	-11,612,000	-3,746,000	-19,878,000	-35,894,000	-33,618,000	-28,213,000	-21,383,000	-75,563,000	-16,816,000	-14,835,000	-15,628,000	-14,410,000	-13,407,000	-19,997,000	-12,918,000	-98,853,000	-25,994,000	-11,018,000	-5,863,000	-4,349,000	-2,629,000	-2,595,000	-6,720,000	-2,649,000	-1,068,000	-3,467,000	-1,819,000	-2,301,000	-14,082,000	-179,000	-968,000	-3,371,000	-1,977,000	-1,960,000	68,294,000	-3,205,000	-1,170,000	-3,509,000	-1,482,000	-3,794,000	-3,462,000	-3,549,000	-2,876,000	-3,081,000	-1,494,000	-3,377,000	-3,544,000	-9,412,000	-2,769,000	-6,561,000	-4,187,000	-5,129,000	-3,519,000	-418,000	-4,281,000	-2,344,000	-2,473,000	-4,171,000	-5,584,000	-5,099,000	444,000	-2,106,000	-4,362,000	-3,756,000	-2,509,000	-1,961,000	-1,602,000	-5,058,000	-515,000	-485,000			-5,048,000	-3,676,000
financing activities:
proceeds from issuance of convertible notes	0	0	392,850,000													0
repurchase of convertible notes	0	0	-268,231,000
repayment of revolving credit facility	-3,700,000	-4,092,000	-52,800,000		-26,400,000	-42,000,000	-42,000,000		-35,000,000	-20,000,000	-27,500,000
purchase of capped calls	0	0	-42,485,000													0
proceeds from revolving credit facility	3,368,000	3,700,000	4,092,000		33,775,000	46,400,000	42,000,000		37,000,000
payment of debt issuance costs	0							0	0	-128,000	-3,193,000	-347,000				0
net cash paid for common stock exercises	-54,000	2,358,000	-3,003,000	4,172,000	291,000	-326,000	-4,697,000	1,270,000
net cash from financing activities	-1,313,000	366,000	30,759,000	50,642,000	6,694,000	3,242,000	-4,370,000	151,571,000	60,325,000	77,913,000	67,110,000	1,013,000	29,444,000	-1,926,000	2,697,000	-487,000	183,684,000	-2,007,000	130,776,000	109,821,000	-90,000	21,137,000	-39,000	964,000	55,443,000	11,478,000	-3,702,000	6,470,000	-129,000	2,961,000	44,583,000	7,801,000	-1,205,000	-2,532,000	13,757,000	4,530,000	-42,167,000	-4,218,000	-1,537,000	17,000	809,000	-3,652,000	-3,706,000	3,677,000	-431,000	7,176,000	20,312,000	5,126,000	5,173,000	-30,000	418,000	2,984,000	-241,000	5,062,000	671,000	-3,930,000	-1,833,000	-378,000	-774,000	-217,000	-1,497,000	40,017,000	4,762,000	384,000	-2,022,000	11,063,000	844,000	10,835,000	3,520,000	1,035,000	6,019,000	-957,000	31,443,000	-362,000	1,195,000	1,451,000	-653,000
effect of exchange rate changes on cash	-158,000	78,000	296,000	445,000	-326,000	-211,000	-459,000	90,000	-151,000	-156,000	32,000	809,000	-484,000	-668,000	-14,000	-1,280,000	-13,000	2,810,000	-2,806,000	12,000	7,000	6,000	69,000	-32,000	-38,000	20,000	79,000	28,000	-44,000	18,000	-22,000	-10,000	301,000	-143,000	96,000	1,135,000	629,000	-878,000	-971,000	-339,000	109,000	-677,000	1,056,000	-575,000	-273,000	-207,000	-18,000
net change in cash and cash equivalents	-1,322,000	3,819,000	14,404,000	57,864,000	-18,852,000	-44,257,000	-76,885,000
cash and cash equivalents at beginning of period	0	0	138,840,000		0	0	220,970,000		0	0	84,696,000		0	0	187,248,000																																		0	0	22,241,000	0	0	0	20,666,000	0	0	0	23,168,000	0	0	0	10,085,000	0	0	0	18,315,000	0	0	0	25,843,000	0	0	0	16,943,000	0	0
cash and cash equivalents at end of period	-1,322,000	3,819,000	153,244,000		-18,852,000	-44,257,000	144,085,000		21,506,000	-15,678,000	116,698,000		-1,358,000	-44,342,000	151,812,000																																		5,706,000	-6,345,000	19,293,000	-3,700,000	3,918,000	5,164,000	16,859,000	-1,478,000	383,000	284,000	21,477,000	-5,686,000	-9,554,000	25,746,000	12,662,000	-4,025,000	-5,621,000	9,644,000	10,087,000	7,441,000	-2,197,000	-13,833,000	26,904,000	-7,818,000	27,412,000	-1,841,000	8,090,000	-4,417,000	-3,660,000
supplemental disclosure of cash flow information:
cash paid for interest	7,049,000	5,187,000	6,530,000	4,974,000	5,584,000	4,295,000	5,463,000	6,067,000	4,362,000	3,106,000	3,734,000	1,137,000	753,000	718,000	1,252,000	730,000	821,000	1,693,000	1,783,000	1,399,000	1,397,000	1,888,000	1,646,000	1,627,000	1,628,000	1,357,000	1,357,000	1,754,000	1,105,000	1,190,000	1,092,000	1,127,000	1,131,000	1,160,000	1,277,000	1,246,000	2,261,000	1,943,000	1,918,000	1,950,000	1,950,000	1,871,000	1,856,000	1,811,000	1,437,000	1,448,000	1,189,000	1,214,000			936,000		692,000														527,000
cash paid for income taxes	0			0	0			86,000	41,000			0	5,000			-2,000	0	204,000	21,000	4,000	20,000	141,000	25,000	59,000	0	79,000	23,000	25,000	37,000	66,000	6,000	17,000	21,000	-129,000	198,000	0	24,000	250,000	646,000	41,000	218,000	97,000	265,000	78,000	194,000	151,000	142,000	976,000			958,000		210,000														152,000
supplemental disclosure of noncash activities:
financed insurance	0	0	1,347,000	0	0	0	1,156,000	0	0	0	1,328,000	158,000	184,000	0	1,617,000
purchases of property and equipment in accounts payable and accrued expenses	341,000	418,000	277,000				5,795,000	3,250,000	4,923,000	382,000	1,851,000		-285,000	-2,363,000	4,667,000
purchase of intangible assets in accrued expenses and other long-term liabilities
recognition of derivative liability	0	0	124,062,000
recognition of lease liabilities	0				406,000
purchase of intangible assets in accrued expenses		-950,000	2,631,000
accrued expenses and other current liabilities															-1,268,000	10,326,000	-2,837,000	-3,464,000	2,958,000
purchases of property and equipment																			-15,202,000	-10,263,000	-5,890,000	-4,349,000	-2,629,000	-2,595,000	-6,720,000	-2,649,000	-1,068,000	-3,217,000	-910,000	-1,977,000	-410,000	-411,000	-1,837,000	-3,371,000	-1,977,000	-1,606,000	-1,600,000	-4,005,000	-1,686,000	-3,509,000	-1,482,000	-3,794,000	-3,462,000	-3,549,000	-2,876,000	-3,081,000	-1,794,000	-3,377,000	-3,294,000	-5,162,000	-2,519,000	-3,636,000	-4,012,000	-4,479,000	-3,519,000	-173,000	-4,151,000	-2,219,000	-1,663,000	-2,371,000	-5,584,000	-4,928,000	-1,145,000	-2,166,000	-3,009,000
acquisition of business, net of cash acquired																0	0
proceeds from revolving credit facility and line of credit
repayment of revolving credit facility and line of credit
proceeds from term debt, net of debt discount
proceeds from common stock offerings, net of offering costs
repayment of oceanes								0	0
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
supplemental disclosure of noncash investing and financing activities:
debt issuance costs												2,413,000															-300,000
financed property and equipment
purchases of intangible assets
recognition of lease liability								0				1,514,000				0	244,000	1,654,000	21,505,000
modification of lease liability for lease amendment												0	0
acquisition of business									0
proceeds from financed insurance					0	0	1,156,000		0	0	1,328,000		184,000	0	1,617,000
proceeds from term loan, net of debt discount									50,000,000	-27,000	98,500,000
repayment of debt issuance costs
proceeds from common stock offering, net of offering costs
purchase of property and equipment in accounts payable and accrued expenses
proceeds from common stock offering
impairment of investment
purchase of oceane																0	0
cash paid for investments																0	0
settlement of forward contract																-399,000	0
repurchase of common stock																0
repayment of squadron medical term loan																0
repayment of inventory financing agreement																0
ppp loan forgiveness																0
financed inventory
net increase in cash and cash equivalents									21,506,000	-15,678,000	32,002,000				-35,436,000																																		5,706,000			-3,700,000	3,918,000			-1,478,000	383,000	284,000	-1,691,000	-5,686,000	-9,554,000	25,746,000	2,577,000			9,644,000	-8,228,000	7,441,000			1,061,000	-7,818,000	27,412,000			-4,417,000	-3,660,000
common stock issued for asset acquisition													0
net cash (paid) received from common stock exercises										-445,000	-1,106,000					-138,000	-2,781,000	-1,996,000	-1,048,000
cash received from sale of assets																																				0	0	800,000	516,000					0	0	0	300,000
proceeds from term debt
purchases of property and equipment in accounts payable																-1,882,000	3,868,000	-7,439,000	8,030,000	1,646,000	-409,000	993,000	1,297,000	-22,000	-924,000	1,436,000	785,000	-337,000	746,000	16,000	515,000	-1,804,000	1,866,000	-3,276,000	3,650,000	2,125,000	-1,908,000	-2,044,000	4,495,000	-135,000	2,058,000	-486,000	886,000	-579,000	-253,000	759,000	1,711,000	-574,000			3,768,000		48,000
common stock warrants issued with term loan draw																				-12,000	0			0	0
common stock issued for partial extinguishment of debt
loss on extinguishment of debt																					0															0
net cash paid from common stock exercises
principal payments on finance lease obligations													-43,000
principal payments on term loan and notes payable													-332,000							-2,000	0
net cash received (paid) from common stock exercises														-1,083,000	1,301,000
net decrease in cash and cash equivalents																																																			-2,948,000				-3,807,000																				-8,853,000
lease liability															-562,000	-18,000	194,000	-57,000	31,000	-337,000	-331,000	-320,000	-324,000	-289,000	-111,000	-271,000	2,910,000
purchase of debt and equity securities
cash paid for acquisition of intangible assets																												-250,000
borrowings under lines of credit																				0	0	12,911,000	29,544,000	32,987,000	27,503,000	27,787,000	26,433,000	22,655,000	23,304,000	22,067,000	22,433,000	25,697,000	23,433,000	22,919,000	24,195,000	24,241,000	24,086,000	35,276,000	34,879,000	36,060,000	32,060,000	34,512,000	38,951,000	41,001,000	42,965,000	40,080,000	39,021,000	45,339,000	40,537,000	34,077,000	34,669,000	38,351,000	35,738,000	43,560,000	3,583,000	688,000	1,232,000	0	430,000	17,564,000	1,000,000	1,200,000	410,000	1,900,000	0	1,928,000	1,940,000	11,350,000	4,250,000	0	8,500,000
repayments under lines of credit																				0	0	-26,207,000	-30,408,000	-31,773,000	-26,673,000	-27,666,000	-26,822,000	-21,412,000	-21,947,000	-22,456,000	-24,178,000	-24,387,000	-23,387,000	-24,243,000	-26,426,000	-23,952,000	-39,877,000	-37,085,000	-33,878,000	-34,213,000	-34,268,000	-35,859,000	-40,227,000	-41,038,000	-42,311,000	-36,156,000	-36,601,000	-38,838,000	-63,091,000	-33,429,000	-33,497,000	-34,628,000	-35,269,000	-29,019,000	-937,000	-14,232,000	-2,684,000	0	-430,000	-1,263,000	0	-1,500,000	-296,000	-455,000	-1,323,000	-255,000	-500,000	-12,750,000	-811,000	0	-1,869,000	-21,047,000	0
proceeds from issuance of term debt																				-4,000	91,000			0	0
common stock issued for development of intangible assets
amortization of debt issuance costs
benefit from excess and obsolete inventory																	2,525,000	2,221,000	2,096,000	1,615,000	1,995,000	1,712,000	1,722,000	2,173,000	2,328,000	2,126,000	1,997,000		-600,000	867,000	1,345,000	902,000	748,000	586,000	306,000	1,175,000	2,114,000	1,729,000	645,000	627,000	-45,000	991,000	583,000	986,000	1,215,000	625,000	713,000	810,000	7,741,000	1,403,000	1,698,000	2,678,000	1,170,000	1,965,000	845,000	1,199,000	1,963,000	710,000	692,000	942,000	796,000	650,000	393,000	911,000	510,000	296,000	210,000	1,339,000	434,000	778,000	517,000
loss on disposal of instruments																	280,000	320,000	369,000	217,000	137,000										-131,000
changes in operating assets and liabilities, net of effects of acquisition:
proceeds from public offering																	0	-10,000	131,838,000					-126,000
net increase in cash																			83,372,000	92,087,000				-10,730,000	39,273,000	2,151,000	-12,635,000	-6,057,000	-9,801,000	-2,733,000	25,179,000	6,997,000			5,825,000	-6,128,000							-8,335,000				2,419,000
cash at beginning of period																																						0	11,229,000	0	0	0	19,735,000	0	0	0	21,345,000
cash at end of period																																						1,561,000	7,761,000	727,000	1,604,000	-2,502,000	11,400,000	-434,000	1,186,000	-4,781,000	23,764,000
common stock issued with term loan draw
balance at january 1, 2021
contract liability assumed from eos																	0
payments received																	3,768,000
revenue recognized																	-4,779,000
balance at september 30, 2021
benefit from doubtful accounts																				28,000	57,000	27,000	-5,000	52,000	68,000	56,000	66,000		21,000	55,000	55,000		-73,000	-84,000	12,000			275,000	195,000	119,000	234,000			79,000	216,000	49,000	178,000	179,000	41,000	127,000	57,000	1,000	-70,000	532,000	396,000	500,000	478,000	110,000	6,000									214,000	10,000	61,000	45,000
principal payments on capital lease obligations																		12,000	-14,000	-8,000	-6,000	-10,000	-8,000	-5,000	-10,000	-7,000	-5,000	-9,000	-27,000	-29,000	-31,000	-219,000	-60,000	-134,000	-159,000	-192,000	-206,000	-202,000	-198,000	-192,000	-171,000	-188,000	-196,000	-161,000	-150,000	-335,000	-120,000				-124,000	-301,000			-110,000	-29,000	-43,000	-49,000	-22,000	-45,000	-33,000	-78,000	-18,000	-64,000	-81,000	-99,000	-98,000	-96,000	-120,000	-126,000	-137,000	-140,000				-131,000
net decrease in cash																						3,697,000	-19,647,000															1,561,000	-3,468,000	727,000	1,604,000				1,186,000
cash at beginning of period, including discontinued operations																		0	107,765,000		0	0	47,113,000		0	0	29,054,000		0	0	22,466,000		-159,000	0	19,752,000
cash at end of period, including discontinued operations																		-114,556,000	191,137,000		-15,485,000	3,697,000	27,466,000		39,273,000	2,151,000	16,419,000		-9,801,000	-2,733,000	47,645,000		-3,670,000	-6,470,000	25,577,000
supplemental disclosure of noncash investing activities:
balance at june 30, 2021
loss on impairment of intangible asset																			150,000
loss on fair value investments																			149,000
cash paid for investment in eos																			-9,081,000
loss on forward contract settlement																			-1,711,000
recognition of right-of-use asset																			21,570,000
level 1:
deferred income tax benefit																								-440,000	0	-2,000	4,000																						-113,000			-1,913,000	499,000				-684,000
beneficial conversion feature from convertible notes																								0	0	0	242,000
accretion to contingent consideration																								0	0	0	289,000	200,000	546,000
other long-term assets																								-444,000	-174,000	-78,000	-2,612,000
accrued expenses and other																				4,251,000	7,110,000	94,000	-2,643,000	3,334,000	2,112,000	2,272,000	-1,071,000	1,993,000	-2,084,000	2,026,000	-258,000	5,304,000	-2,342,000	-3,343,000	-5,867,000	-3,731,000	1,987,000	-1,147,000	-607,000	6,279,000	-2,861,000	-3,071,000	-6,712,000	-446,000	-3,424,000	-27,276,000	-3,984,000	54,999,000	5,602,000	-1,112,000	-4,318,000	1,896,000	-2,496,000	3,801,000	-4,965,000	2,889,000	-818,000	-1,472,000	647,000	-3,479,000	1,371,000	-3,309,000	2,826,000		-3,538,000	1,756,000	1,892,000		1,966,000	2,630,000	-1,688,000	2,180,000	1,102,000	-1,020,000	-457,000	2,224,000	-1,132,000
cash received from sale of equipment																												0	0	176,000	172,000
proceeds from sale of common stock																				2,137,000	-175,000	546,000	833,000	-96,000	672,000
cash at beginning of year
cash at end of year
common stock issued for achievement of safeop contingent consideration																								0	0	0	2,889,000
amortization of right-of-use asset																					344,000	268,000	259,000	252,000	237,000	224,000	217,000
gain on disposal of instruments																							32,000		412,000	341,000	-275,000
gain on settlement																												0	0	0	-6,168,000
deferred revenue																												0	-64,000																																							-1,004,000	1,477,000
cash paid for acquisition of safeop surgical, inc.																												0	-759,000	-500,000	-13,844,000
common stock and warrants issued for the acquisition of safeop
principal payments on term loan																									-23,000	-23,000	-3,022,000		-1,475,000
proceeds from sale of stock																											14,000	348,000	16,000	4,279,000	47,259,000		-420,000	158,000	17,472,000		-1,000
provision (recovery) for doubtful accounts
(recovery) benefit from excess and obsolete inventory
gain on sale of assets																																	0
gain from change in estimated fair value of warrants
issuance of warrants upon execution of term loan
reclassification of warrant liabilities to equity
common stock issued for acquisition of intangible assets																																0
capital lease additions included in property and equipment
subscription receivable
deferred income tax expense																													11,000	-1,269,000	31,000		0					50,000	-76,000		-1,686,000	133,000	233,000												162,000
(gain) loss on disposal of instruments
other non-cash items																																		-600,000	994,000	146,000	-540,000	832,000	-12,000	620,000	-5,570,000	720,000	-133,000	-742,000								268,000
deferred revenues																															-22,000		43,000					68,000	80,000		-94,000	-264,000	30,000		-194,000	211,000	-18,000		26,000	-133,000	-46,000		306,000	168,000	-285,000		79,000	25,000	-130,000		1,685,000	-319,000	-517,000		-798,000	364,000	643,000
principal payments on notes payable and term loan																															-900,000	-2,266,000	1,029,000	-1,232,000	-1,325,000		-49,215,000	-2,265,000	-2,340,000
transaction related expenses in accounts payable																															542,000
goodwill and intangible assets impairment
interest expense related to amortization of debt discount and debt issuance costs																																		706,000	717,000	310,000	760,000	1,128,000	1,432,000	1,065,000	1,136,000	1,100,000	1,394,000	2,346,000	1,998,000	1,926,000	430,000	83,000	76,000	80,000	129,000	70,000	78,000	669,000	102,000	94,000	92,000	92,000	97,000	608,000	278,000	297,000	147,000		147,000	147,000	150,000
(recovery) benefit from doubtful accounts
gain on sale of business																																				-2,574,000
loss on sale of instruments
restricted cash																																				0	150,000	1,100,000	1,100,000	1,100,000	1,100,000	1,100,000	1,100,000	-4,749,000	0	15,749,000	-17,750,000
other long term liabilities
proceeds from sale of business																																				-104,000
issuance of preferred and common stock
proceeds from issuance of notes payable																																																																				13,921,000	1,131,000			0	-7,000	0	584,000	1,618,000	-402,000
cash at beginning of year, including discontinued operations
cash at end of year, including discontinued operations
cashless warrant conversion																																				0
impairment of goodwill and intangible assets
proceeds from/(payments on) notes payable
allowance for doubtful accounts																																	38,000
in-process research and development
deferred income tax provision
issuance of common stock
principal payments on notes payable																																								-2,013,000	-1,812,000	-2,117,000	-2,234,000	-2,001,000	-935,000	-1,413,000	-1,488,000				-630,000	-498,000			-1,881,000	-357,000	-345,000	-425,000	-753,000	-15,995,000	-2,481,000	-2,820,000	-1,972,000	-1,070,000	-606,000	-395,000	-498,000	-1,590,000	-930,000	-654,000	-497,000	-603,000	-383,000	-362,000	-900,000	-1,525,000
purchase of property and equipment through capital leases
non-cash debt discount																																												150,000	0	0	500,000
initial fair value of warrant liability																																												912,000	0	0	10,368,000
benefit from (recovery of) doubtful accounts
proceeds from notes payable																																													0	5,000,000	19,500,000
adjustments to reconcile net income to net cash from by operating activities:
cash paid for acquisitions																																																0	0
exercise of stock options																																																				60,000	0	0	16,000	0	7,000	96,000	1,000	2,000	17,000	102,000	92,000	7,000
non-cash purchases of license agreements
goodwill and intangible impairment
non-cash in-process research and development expenses
purchase of property and equipment through capital lease																																													0
issuance of common stock in connection with acquisitions
deferred income tax (benefit) expense																																														248,000	106,000				-204,000								-830,000	-844,000
other noncash items																																														1,833,000	-335,000		187,000
litigation settlement
principal payments on notes payable and capital lease obligations																																																	-273,000
effect of exchange rate changes on cash and cash equivalents																																																	-110,000	279,000	-261,000	175,000	29,000	226,000	472,000	571,000	-56,000	62,000	-56,000	382,000	-568,000	-425,000	-128,000	208,000	-134,000	-88,000	-204,000	-129,000	-15,000	-59,000	-119,000	7,000	-78,000	-103,000	-69,000	48,000	97,000
supplemental cash flow information:
property and equipment purchased under capital lease																																																					501,000
gain on sale of imc co.																																																												0	0
cash received from acquisition of scient’x
proceeds from sale of imc co.																																																												0	0
net proceeds from issuance of common stock																																																												0	0	43,113,000	6,546,000	66,000	-43,000											2,000	0
purchase of noncontrolling interest
cash paid for acquisition of brazilian subsidiary																																																								0	-130,000	-125,000	-365,000
in-process research and development paid in stock																																																												0				-2,000	0	2,663,000	350,000	0	0	0	650,000	0
loss on sale of property and equipment
proceeds from sale of noas medical company
cash received in acquisition of scient’x																																																												0	0	0	1,589,000
return of scient’x license fee
proceeds from sale of property and equipment
certificate of deposit proceeds
repurchase of stock options
benefit from (recoveries from) doubtful accounts																																																													33,000	717,000	14,000	25,000	5,000	0	-25,000
gain on sale of property and equipment																																																																	-59,000
proceeds from sale of noas investment																																																																	0	0	383,000
deferred income taxes																																																														-220,000	35,000	31,000	28,000	47,000	35,000	36,000	35,000	36,000	294,000					283,000
purchase of intangible asset
interest expense related to amortization of debt discount, debt issuance costs and revaluation of put right
accrued expenses and other liabilities
acquisitions of japan ortho medical, net of cash acquired
acquisition of alphatec manufacturing, inc., net of cash acquired																																																																								0				0
proceeds from sale of (investment in) noas medical company
return (purchase) of scient’x license fee
escrow proceeds																																																																								0	0	0	952,000
scient’x license fee repayment
sale of certificate of deposit																																																																						0	2,000,000
accrued litigation settlement																																																																							11,000,000
purchases of instruments, property and equipment																																																																			-2,892,000	-2,914,000	-2,904,000	-4,669,000	-2,515,000	-1,585,000	-1,858,000	-1,508,000	-421,000
purchase of instruments, property and equipment in accounts payable																																																																			3,144,000
income taxes receivable																																																																									-9,000	0	-20,000	73,000
acquisition of japan ortho medical, net of cash acquired
investment in noas medical company																																																																								0	0
acquisition of certain assets and liabilities of cortek, inc., net of cash acquired
proceeds from issuance of rolling common, series c common and preferred stock																																																																												-2,000	0
repayment of supply agreement obligation																																																																												0
cash paid for redemption of redeemable convertible preferred stock
repayment of stockholder notes receivable																																																																												0	0
interest expense related to amortization of debt discount and revaluation of put right																																																																								0	0	58,000	91,000	-564,000	-89,000
investment (sale) - certificate of deposit
revaluation of put right
investment in certificate of deposit																																																																											-2,000,000
net (decrease) in cash and cash equivalents
write-off of purchased in-process research and development
allowance for excess and obsolete inventory
acquisition of certain assest and liabilities of cortek, inc., net of cash acquired																																																																													0
acquisition of ishibe medical co. ltd, net of cash acquired
deferred costs paid in connection with initial public offering
stock redemption																																																																												1,000
acquisition of japan ortho medical (formerly blues medica), net of cash acquired
increase in restricted cash																																																																									0
net proceeds from the issuance of common stock
accretion to redemption value of redeemable stock
purchases of property and equipment through capital leases
net cash (used) in operating activities
acquisition of blues medica, net of cash acquired
net cash (used) in investing activities
net proceeds from common stock subscription																																																																										0	1,119,000
borrowings (repayments) under lines of credit																																																																											-560,000
advances received on common stock sales
net borrowings under lines of credit

The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.